Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib + Ivonescimab in Advanced METex14 Skipping Positive NSCLC
NCT07619339Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tepotinib and ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Optimal Dose Finding at 2 years. Started May 2026; status: recruiting.
02
Drugs
tepotinibivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07619339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619339.